Targeting FOXM1/PSAT1 axis by Brusatol inhibits lung cancer malignant progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Brusatol (BRU), derived from Brucea javanica, exhibits anti-cancer properties.
• The precise mechanisms of Brusatol's action in lung cancer remain incompletely understood.
• Identifying downstream targets is crucial for understanding Brusatol's therapeutic potential.

Purpose of the Study:

• To elucidate the downstream targets and mechanisms of Brusatol in lung cancer.
• To investigate the role of phosphoserine aminotransferase 1 (PSAT1) in Brusatol's anti-cancer effects.
• To explore the involvement of the transcription factor FOXM1 in regulating PSAT1.

Main Methods:

• Quantitative real-time PCR and Western blotting to assess mRNA and protein levels.
• In vitro and in vivo experiments to evaluate the impact of PSAT1 overexpression on Brusatol's efficacy.
• Chromatin immunoprecipitation assays to determine FOXM1 binding to the PSAT1 promoter.

Main Results:

• Brusatol significantly reduced both mRNA and protein expression of PSAT1.
• Overexpression of PSAT1 counteracted the anti-tumor effects of Brusatol in lung cancer cells.
• FOXM1 directly binds to the PSAT1 promoter, enhancing its transcription.
• FOXM1 upregulation abrogated Brusatol's inhibitory effects on PSAT1 and promoted tumor cell survival.

Conclusions:

• The FOXM1/PSAT1 axis is identified as a critical mediator of Brusatol's anti-cancer activity in lung cancer.
• Brusatol demonstrates potential as a novel therapeutic strategy for lung cancer by targeting the FOXM1/PSAT1 pathway.
• Further research into this pathway could lead to improved lung cancer treatments.